Study Details

Back to Search Results

A Study of ASP2215 in Combination with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukemia.

Recruitment complete
The study is ongoing, and participants are receiving an intervention or being examined, but potential participants are not currently being recruited or enrolled.

Clinicaltrials.gov ID

The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
NCT02310321

Astellas Study ID

The unique identification code given by the study sponsor.

2215-CL-0104

EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).

N/A

Follow Trial

Condition

Leukemia - AML

Phase

These clinical trials are usually the first time an experimental treatment is studied in a small group of people.

Phase 1

Age

18 years - 69 years

Sex

Female & Male

Product

gilteritinib

Type

A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

Interventional

Trial Dates

Feb 2015 - Dec 2024

Masking

None (Open Label)

Enrollment number

84

A Phase 1/2 Study of ASP2215 in Combination with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukemia

Study summary

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for A Study of ASP2215 in Combination with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukemia.? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

Locations

Site JP81035

Sendai, Japan

Site JP81013

Isehara, Japan

Site JP81008

Chiba, Japan

Site JP81037

Anjo, Japan

Site JP00001

Fukuoka, Japan

Site JP81029

Akita, Japan

Site TW88604

Kaohsiung, Taiwan, Province of China

Site JP81023

Tsukuba, Japan

Site JP81038

Toyohashi, Japan

Site JP81001

Maebshi, Japan

Site JP81009

Okayama, Japan

Site JP81028

Kumamoto, Japan

Site JP81032

Shinagawa-ku, Japan

Site JP81016

Kyoto, Japan

Site JP81019

Osaka, Japan

Site KR82002

Incheon, Republic of Korea

Site JP00006

Yokohama, Japan

Site JP81030

Gifu, Japan

Site JP81003

Nagoya, Japan

Site KR82006

seoul, Republic of Korea

Site JP81020

Kanazawa, Japan

Site JP81012

Nagasaki, Japan

Site JP81018

Otake, Japan

Site JP81002

Shinagawa-ku, Japan

Site JP81036

Mito, Japan

Site JP81007

Yoshida-gun, Japan

Site TW88602

Taichung, Taiwan, Province of China

Site JP81040

Bunkyo-ku, Japan

Site JP81041

Tenri, Japan

Site TW88603

Taoyuan, Taiwan, Province of China

Site JP81022

Shimono, Japan

Site JP81004

Fukuoka, Japan

Site KR82005

Seoul, Republic of Korea

Site JP81027

Nagoya, Japan

Site KR82004

Seoul, Republic of Korea

SIte JP81011

Omura, Japan

Site JP81033

Kochi, Japan

Site JP81039

Matsuyama, Japan

Site JP81025

Fukuoka, Japan

Site JP81024

Yokohama, Japan

Site KR82001

Seoul, Republic of Korea

Site JP81021

Osaka, Japan

Site JP81026

Fukuyama, Japan

Site JP81031

Fukushima, Japan

Site JP00007

Kobe, Japan

Site JP81017

Nakagyo-ku, Japan

Site JP00005

Shinagawa-ku, Japan

Site JP00002

Maebashi, Japan

Site JP81005

Yokohama, Japan

Site TW88601

Tainan, Taiwan, Province of China

Site KR82003

Seoul, Republic of Korea

Site JP81015

Sapporo, Japan

Site JP81014

Sapporo, Japan

Site JP81006

Kobe, Japan

Site JP81010

Narita, Japan

Site JP00003

Nagoya, Japan

Site JP81034

Suwa, Japan

Site JP81043

Himeji, Japan

The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. In addition, the website will provide specific information about Astellas clinical trials. Please read the complete Astellas Transparency Policy to learn about the clinical trial information available on this website

© ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.

POWERED BY:

Pharma Intelligence logo